Research paper
Isoflavone Soy Protein Supplementation and Atherosclerosis Progression in Healthy Postmenopausal Women: A Randomized Controlled Trial
Study answer
What this study found
Isoflavone soy protein did not significantly slow carotid intima-media thickness progression overall. CIMT progression rates were 4.77 (3.39-6.16) mm/year in the ISP group and 5.68 (4.30-7.06) mm/year in placebo, for a between-group difference of -0.91 (-2.86 to 1.05; P = 0.36). A predefined subgroup randomized within 5 years of menopause showed a possible benefit: difference -4.62 (-9.21 to -0.04; P = 0.05), with a similar trend in Asian participants. The intervention was reported as safe and well tolerated, with no major adverse events attributable to ISP, although respiratory symptoms…
- Study & population
- Randomized, placebo-controlled trial in healthy postmenopausal women without diabetes or cardiovascular disease.
- Intervention
- Isoflavone soy protein was administered orally as 25 g twice daily for a total of 50 g/day for 2.7 years, delivered in beverage powder-food packs or food bars versus placebo.
- Key limitation
- The overall effect was null, and the apparent benefit was limited to subgroup analyses that are vulnerable to chance findings and reduced power.
View source
Open PDFOriginal abstract
Background and Purpose— Although epidemiological and experimental studies suggest that dietary intake of soy may be cardioprotective, use of isoflavone soy protein (ISP) supplementation as a primary preventive therapy remains unexplored. We determine…